Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis and critical examination of current methodologies

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 6, 2014, Pages 975-983

  Vardi, Moshe ^a   Novack, Victor ^b   Pencina, Michael J ^a,c   Doros, Gheorghe ^a,c   Burke, David A ^a,d   Elmariah, Sammy ^a,e   Cutlip, Donald E ^a,d   Mauri, Laura ^a,f   Yeh, Robert W ^a,e  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b Soroka Clinical Research Center   (Israel)

^c BOSTON UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

peripheral vascular disease; restenosis; stent structure

Indexed keywords

ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DEVICE SAFETY; FEMOROPOPLITEAL OCCLUSIVE DISEASE; HUMAN; LIMB AMPUTATION; MEDICAL PRACTICE; META ANALYSIS; METHODOLOGY; MORTALITY; NITINOL STENT; OUTCOME ASSESSMENT; PERFORMANCE GOAL; PERFORMANCE MEASUREMENT SYSTEM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SENSITIVITY ANALYSIS; SUPERFICIAL FEMORAL ARTERY DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW; VASCULAR PATENCY; ENDOVASCULAR SURGERY; FEMORAL ARTERY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT; TREATMENT OUTCOME;

ALLOY; NITINOL;

ALLOYS; CONSTRICTION, PATHOLOGIC; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; HUMANS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; RISK FACTORS; STENTS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84899432318     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25179     Document Type: Article

References (34)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB,. Heart disease and stroke statistics-2012 update: A report from the American heart association. Circulation 2012; 125: e2-e220.
2. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP,. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: Data from the national health and nutrition examination survey 1999-2004. J Am Geriatr Soc 2007; 55: 583-589.
3. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B., Acc/aha 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the acc/aha task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. Circulation 2006; 113: e463-e654.
4. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF,. Intermittent claudication. A risk profile from the Framingham heart study. Circulation 1997; 96: 44-49.
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67.
6. Murphy TP, Ariaratnam NS, Carney WI Jr, Marcaccio EJ, Slaiby JM, Soares GM, Kim HM,. Aortoiliac insufficiency: Long-term experience with stent placement for treatment. Radiology 2004; 231: 243-249.
7. Murabito JM, Evans JC, D'Agostino RB Sr, Wilson PW, Kannel WB,. Temporal trends in the incidence of intermittent claudication from 1950 to 1999. Am J Epidemiol 2005; 162: 430-437.
8. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Beregi JP,. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The sirocco ii trial. J Vasc Intervent Radiol 2005; 16: 331-338.
9. Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T,. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (fast). Circulation 2007; 116: 285-292.
10. Zeller T, Tiefenbacher C, Steinkamp HJ, Langhoff R, Wittenberg G, Schluter M, Buergelin K, Rastan A, Krumsdorf U, Sixt S, Schulte CL, Tubler T, Krankenberg H,. Nitinol stent implantation in tasc a and b superficial femoral artery lesions: The femoral artery conformexx trial (fact). J Endovasc Ther 2008; 15: 390-398.
11. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M,. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009; 74: 1090-1095.
12. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E,. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-1888.
13. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS,. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month zilver ptx randomized study results. Circ Cardiovasc Interv 2011; 4: 495-504.
14. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR,. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the resilient randomized trial. Circ Cardiovasc Interv 2010; 3: 267-276.
15. Bosiers M, Torsello G, Gissler HM, Ruef J, Muller-Hulsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroe H, Mathias K, Koppensteiner R, Vermassen F, Scheinert D,. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the durability i study. J Endovasc Ther 2009; 16: 261-269.
16. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G,. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007; 69: 910-919.
17. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Chichester, West Sussex, England: John Wiley & Sons Ltd.; 2008.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,. The strengthening the reporting of observational studies in epidemiology (strobe) statement: Guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
19. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, on behalf of VIVA, Physicians I,. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007; 69: 910-919.
20. Goode J, Sapirstein W, Zuckerman B,. FDA perspective on clinical trial design for femoropopliteal stent correction of peripheral vascular insufficiency cardiovascular devices. Catheter Cardiovasc Interv 2007; 69: 920-921.
21. Normand SL,. Meta-analysis: Formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-359.
22. Lunn D, Spiegelhalter D, Thomas A, Best N,. The bugs project: Evolution, critique and future directions. Stat Med 2009; 28: 3049-3067.
23. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J,. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002; 13: 257-266.
24. Bosiers M DK, Callaert J, Moreels N, Keirse K, Verbist J, Peeters P,. Results of the protégé everflex 200-mm-long nitinol stent (ev3) in tasc c and d femoropopliteal lesions. J Vasc Surg 2011; 54: 1042-1050.
25. Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ,. The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protege everflex nitinol stent system ii (DURABILITY II). J Vasc Surg 2013; 58: 73-83.
26. Perrio S, Holt PJ, Patterson BO, Hinchliffe RJ, Loftus IM, Thompson MM,. Role of superficial femoral artery stents in the management of arterial occlusive disease: Review of current evidence. Vascular 2010; 18: 82-92.
27. Acin F, de Haro J, Bleda S, Varela C, Esparza L,. Primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis of randomized controlled trials. J Endovasc Ther 2012; 19: 585-595.
28. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Beregi JP,. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation 2002; 106: 1505-1509.
29. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M,. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 2005; 12: 6-12.
30. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A,. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: A midterm follow-up. Radiology 2002; 222: 37-43.
31. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M,. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 2010; 52: 608-615.
32. Diehm N BI, Jaff M, Do DD, Minar E, Schmidli J, Diehm C, Biamino G, Vermassen F, Scheinert D, van Sambeek MR, Schillinger M,. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J 2007; 28: 798-805.
33. Gerhard-Herman M GJ, Jaff M, Mohler E, Roman M, Naqvi TZ,; American Society of Echocardiography; Society for Vascular Medicine and Biology. Guidelines for noninvasive vascular laboratory testing: A report from the American society of echocardiography and the society for vascular medicine and biology. Vasc Med 2006; 11: 183-200.
34. Kawarada O, Higashimori A, Noguchi M, Waratani N, Yoshida M, Fujihara M, Yokoi Y, Honda Y, Fitzgerald PJ,. Duplex criteria for in-stent restenosis in the superficial femoral artery. Catheter Cardiovasc Interv 2013; 81: E199-E205.